This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Antibody-Based Therapeutics for Cancer
Organizer(s): Louis M. Weiner and Paul Carter
Date: February 04 - 09, 2003
Location: Banff Centre, Banff, AB, Canada
Sponsored by Amgen Inc.
Summary of Meeting:
Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected unconjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphomas. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new targets, including structurally-defined (e.g., through proteomic or genomic screening) and functionally-defined approaches. New approaches are needed to harness the ability of antibodies to initiate and sustain innate and adaptive immune responses. For immunoconjugate strategies to consistently succeed without undue host toxicity, new strategies must be developed to dissociate the process of antibody distribution from the effects of antibody-directed tumor targeting. This meeting will address these challenges in distinct sessions devoted to antibody structure and function, immunoconjugates, antibodies as tools for target discovery, antibodies as signaling agents and immune effectors, and in a session that highlights clinical advances in the field. Leaders in each of these areas will present their work and discussion periods will be used to highlight areas felt to have particular promise.
Discounted Abstract Deadline: October 3 2002
Discounted Registration Deadline: December 4 2002
We gratefully acknowledge additional support for this conference from:
Educational donation provided by AmgenJanssen Research & Development LLC
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA098899-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found